每经AI快讯，9月1日，和元生物公告，华睿盛银及其一致行动人在2025年5月30日至2025年8月29日期 间，通过集中竞价交易方式合计减持公司股份648.34万股，占公司总股本的0.9989%，减持计划已实施 完毕。减持后，华睿盛银及其一致行动人持股比例从5.8495%降至4.8505%，不再是公司持股5%以上的 股东。 ...

国泰海通证券股份有限公司 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：和元生物 | | --- | --- | | 保荐代表人姓名：陈恒瑞、王莉 | 被保荐公司代码：688238 | 重大事项提示 2025 年 1-6 月，公司实现营业收入 11,985.50 万元，同比增长 6.01%，实现 归属于母公司所有者的净利润-10,457.01 万元，较上年同期减少亏损 877.53 万元， 实现归属于母公司所有者的扣除非经常性损益的净利润-10,451.18 万元，较上年 同期减少亏损 1,489.73 万元；经营活动产生的现金流量净额-8,849.96 万元，较上 年同期经营活动产生的现金流量净流出减少 2,613.02 万元；报告期内，公司细胞 和基因治疗 CDMO 业务继续受宏观环境变化、产业状况、下游需求等因素影响， 执行订单价格仍处于较低水平，而公司临港产业基地产能释放需要时间，折旧摊 销成本、能耗成本、行政办公费用等运营成本费用相对较高，截止目前细胞和基 因治疗 CDMO 业务营业毛利率仍为负值，公司整体仍处于亏损状态，但较上年 度同期有所改善。 细胞和基因治疗是生物医药行业未来 ...

Group 1 - The stock price of He Yuan Bio as of August 27, 2025, closed at 7.98 yuan, down 4.43% from the previous trading day [1] - The trading volume for the day was 225,457 hands, with a transaction amount of 185 million yuan [1] - He Yuan Bio operates in the medical services sector, focusing on gene therapy, with core business activities including the research, production, and sales of gene therapy vectors [1] Group 2 - The company possesses multiple core technologies and has business layouts in CAR-T cell therapy and CRO (Contract Research Organization) [1] - On the same day, the net outflow of main funds was 21.24 million yuan, with a cumulative net outflow of 36.01 million yuan over the past five trading days [1]

Group 1: Company Insights - Kefu Medical (301087) is expected to achieve over 20% year-on-year revenue growth in hearing aid sales in the first half of 2025, with plans to enhance revenue from existing stores and new outlets in the second half [1] - The company has invested in Newlink Medical to address congenital hearing loss, aiming for strategic synergy [1] - Overseas revenue has increased by over 200%, with completed acquisitions of Shanghai Huazhou and Ximaner, focusing future mergers on targets that can supplement product lines or enhance technical capabilities [1] - Kefu Medical has developed a comprehensive product matrix across five major areas and is increasing investment in e-commerce platforms, advancing smart projects in respiratory, blood pressure, blood glucose, and oxygen generation [1] - Key products include respiratory machines and hearing aids, with a focus on revenue contribution and strategic value; respiratory machine sales are rapidly growing, leading the category on Douyin's e-commerce platform [1] Group 2: Industry and Fund Management - Heyuan Bio leverages generative AI for innovative sequence design, utilizing deep learning frameworks such as Transformer and Diffusion for sequence scoring and generation [1] - Zhongjia Fund, established in 2013, has an asset management scale of 141.193 billion yuan, ranking 49th out of 210 in total public funds and 42nd out of 210 in non-monetary public funds [1] - The fund manages 135 public funds, ranking 60th out of 210, with 19 fund managers, ranking 72nd out of 210 [1] - The best-performing public fund product in the past year is Zhongjia Technology Innovation Mixed Fund A, with a latest unit net value of 1.68 and a growth of 128.28% over the past year [1] - The latest public fund product launched is Zhongjia CSI 300 Dividend Low Volatility Index A, which is an index-type stock fund, with a subscription period from August 18, 2025, to September 5, 2025 [1]

Group 1 - The core viewpoint of the article highlights that Dan Yi Investment has recently conducted research on a listed company, He Yuan Biology, focusing on its innovative use of generative AI in sequence design [1] - He Yuan Biology is leveraging deep learning frameworks such as Transformer and Diffusion to develop AI models for sequence scoring and generation [1] - Dan Yi Investment, established in April 2015, is a well-known private equity investment management firm in China with a registered capital of 10 million [1] Group 2 - The management team of Dan Yi Investment has over ten years of experience in investment research, having previously held positions at notable institutions such as Huabao Xingye Fund and Guotou Ruijin Fund [1] - The firm has managed funds totaling several billion during its operational history, indicating a strong track record in the investment sector [1]

Group 1 - The company reported a revenue of 120 million yuan in the first half of 2025, representing a year-on-year increase of 6.01% [1] - The net profit attributable to shareholders was -105 million yuan, an improvement from -113 million yuan in the same period last year [1] - The net cash flow from operating activities was -88.5 million yuan, compared to -115 million yuan in the previous year [1] Group 2 - In 2024, the company achieved a revenue of 248 million yuan, marking a year-on-year growth of 21.16% [2][3] - The net profit attributable to shareholders for 2024 was -322 million yuan, worsening from -128 million yuan in the previous year [2][3] - The net cash flow from operating activities was -61 million yuan, an improvement from -90 million yuan in the previous year [2][3] Group 3 - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 22, 2022, with an initial public offering of 100 million shares at a price of 13.23 yuan [3] - The total amount raised from the IPO was 1.323 billion yuan, with a net amount of 1.197 billion yuan after expenses [4] - The company announced a capital increase of 0.3 shares for every share held, resulting in a total share capital of 641.15 million shares after the distribution [5]

Group 1 - The stock of He Yuan Bio (688238.SH) closed at 8.07 yuan, with a decline of 3.12%, currently in a state of breaking issue [1] - He Yuan Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 22, 2022, with an initial public offering of 100 million shares at a price of 13.23 yuan [1] - The total amount raised from the IPO was 1.323 billion yuan, with a net amount of 1.197 billion yuan after expenses [1] Group 2 - The total issuance costs for He Yuan Bio's IPO amounted to 126 million yuan, including underwriting fees of 93.795 million yuan [2] - The company announced a capital increase plan, distributing 0.3 shares for every share held, resulting in an increase of 14,795,670 shares, bringing the total share count to 641,145,700 shares [2] - The ex-rights date for the capital increase was set for May 30, 2023 [2]

Core Viewpoint - The recent financial report of He Yuan Biological (688238) shows a modest increase in revenue and a reduction in net loss, indicating an improvement in profitability metrics despite ongoing challenges in cash flow and operational efficiency [1][10][11]. Financial Performance - Total revenue for the first half of 2025 reached 120 million yuan, a year-on-year increase of 6.01% [1] - The net profit attributable to shareholders was -10.5 million yuan, improving by 7.74% year-on-year [1] - Gross margin improved by 41.25% to -14.28%, while net margin increased by 13.24% to -87.17% [1] - Total operating expenses were 59.3 million yuan, accounting for 49.47% of revenue, a decrease of 13.11% year-on-year [1] Cash Flow and Financial Position - Cash and cash equivalents decreased by 40.95% due to stock buybacks and operational cash outflows [3] - Short-term borrowings increased by 192.23% to meet funding needs [3] - The net cash flow from operating activities improved by 22.8% due to reduced cash outflows for employee compensation and material procurement [8] Business Operations - The CRO business, focusing on cell and gene therapy, reported a revenue increase of 8.02% to 85.82 million yuan in 2024, with a growing customer base of over 12,800 research labs [12][13] - The company is expanding its CDMO services, with over 450 projects undertaken, including 4 Phase III clinical projects [15] Market and Competitive Landscape - The CDMO sector for cell and gene therapy is experiencing a high outsourcing penetration rate of 65%, indicating a reliance on specialized services due to the complexity of production processes [14] - The company is actively enhancing its market presence both domestically and internationally, focusing on innovative technology services to meet diverse customer needs [13] Shareholder Actions - A shareholder reduction plan was announced, with intentions to sell up to 6.49 million shares, representing 1% of the total share capital [21]

Core Viewpoint - On August 19, no A-share listed companies disclosed any increase in shareholding, while 12 companies announced share reductions by various stakeholders [1]. Group 1: Companies with Share Reductions - Sanxin Medical: Multiple shareholders plan to reduce their holdings [2]. - Nanjing Port: Some directors and senior management personnel plan to reduce their holdings [2]. - Hongye Futures: Shareholders intend to reduce no more than 1% of the company's shares [2]. - AVIC Optoelectronics: A shareholder plans to reduce no more than 28,000 shares [2]. - Heyuan Biological: Huairui Shengyin and its concerted parties will reduce their holdings to below 5% [2]. - New Zhisoft: Multiple shareholders plan to reduce their holdings [2]. - Lutianhua: Shareholders holding over 5% plan to reduce no more than 1% of the company's shares [2]. - Demai Chemical: Chang Lianrong Investment plans to reduce no more than 14,463,463 shares, accounting for no more than 3% of the company's equity [2]. - Fuxin Technology: Controlling shareholders Liu Fukun and Liu Fulin collectively reduced 1.05% of the company's shares [2]. - Huazheng New Materials: Supervisors and senior management plan to reduce no more than 124,900 shares, with the reduction not yet implemented [2]. - Zhenbaodao: Shareholders plan to reduce no more than 4% of the company's shares [2]. - Hefeng Co.: Two shareholders plan to reduce no more than 2.19% of the company's shares [2]. Group 2: Market Signals - The formation of a MACD golden cross signal indicates a positive trend for certain stocks [2].

Core Viewpoint - He Yuan Biotechnology (Shanghai) Co., Ltd. reported a revenue of 120 million yuan in the first half of 2025, marking a year-on-year growth of 6.01%, and a non-net loss of 105 million yuan, indicating a reduction in losses compared to the previous year [1] Group 1: Financial Performance - The company achieved a revenue of 120 million yuan in the first half of 2025, reflecting a 6.01% increase year-on-year [1] - The non-net loss was 105 million yuan, which is a reduction of 14.89 million yuan compared to the previous year [1] - The CRO business generated revenue of approximately 40.7 million yuan, a year-on-year increase of 3.79%, while the CDMO business revenue was about 65.6 million yuan, remaining stable compared to the same period last year [1] Group 2: Market and Business Development - The CGT market's activity increased in the first half of 2025, providing growth opportunities for CRO/CDMO companies, although rapid revenue growth is still expected to take time [1] - The CDMO new orders exceeded 90 million yuan in the first half of 2025, with revenue recognition contingent upon the delivery of technical service results and client confirmation [1] - The company is optimistic about the recovery of the CDMO market demand and believes that the increase in downstream customer orders will gradually improve production capacity utilization [1] Group 3: R&D and New Business Directions - R&D investment amounted to approximately 23.2 million yuan, accounting for 19.37% of total revenue, with 2 new invention patent applications and 8 utility model patent applications filed [2] - Revenue from regenerative medicine services, biological reagent testing, and other main businesses reached about 13.4 million yuan, showing a significant year-on-year growth of 61.17%, contributing to the reduction in losses [2] - The company is exploring new business models in regenerative medicine, including partnerships with research institutions and participation in industry standard formulation [2]